Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
+0.26 (0.31%)
Apr 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 84.13 - 84.89
52 week 67.67 - 85.23
Open 84.35
Vol / Avg. 969,607.00/1.50M
Mkt cap 205.42B
P/E 22.88
Div/yield 2.76/3.26
EPS 3.70
Shares 2.43B
Beta 0.56
Inst. own 10%
Jul 17, 2014
Q2 2014 Novartis AG Earnings Release Add to calendar
Jul 1, 2014
Novartis AG at Credit Suisse Swiss Midcap Healthcare Conference Add to calendar
Jun 26, 2014
Novartis AG at JPMorgan European Healthcare Conference Add to calendar
Jun 17, 2014
Novartis AG Investor Day - 12:30PM EDT - Add to calendar
Jun 11, 2014
Novartis AG at Goldman Sachs Healthcare Conference Add to calendar
Jun 11, 2014
Novartis AG at Vontobel Summer Conference Add to calendar
May 20, 2014
Novartis AG at UBS Global Healthcare Conference Add to calendar
May 19, 2014
Novartis AG at Deutsche Bank dbAccess Asia Conference Add to calendar
May 7, 2014
Novartis AG at UBS Investor Day Add to calendar
Apr 24, 2014
Q1 2014 Novartis AG Earnings Conference Call - 8:00AM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 13.40% 15.79%
Operating margin 15.45% 18.52%
EBITD margin - 27.97%
Return on average assets 6.58% 7.42%
Return on average equity 11.12% 12.79%
Employees 135,696 -
CDP Score - 96 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. It has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. In February 2014, it acquired CoStim Pharmaceuticals, Inc.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Joseph S. Jimenez Chief Executive Officer, Member of the Executive Committee
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 67
Bio & Compensation  - Reuters
Harry Kirsch Member of the Management Board, Chief Financial Officer
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 57
Bio & Compensation  - Reuters
Juergen Brokatzky-Geiger Ph.D. Head Human Resources and Member of the Executive Committee
Age: 62
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters